A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy

Dipankar Pramanik, Nathaniel R. Campbell, Samarjit Das, Sonal Gupta, Venugopal Chenna, Savita Bisht, Polina Sysa-Shah, Djahida Bedja, Collins Karikari, Charles Jr Steenbergen, Kathleen L Gabrielson, Amarnath Maitra, Anirban Maitra

Research output: Contribution to journalArticle

Abstract

Acquired chemotherapy resistance is a major contributor to treatment failure in oncology. For example, the efficacy of the common anticancer agent doxorubicin (DOX) is limited by the emergence of multidrug resistance (MDR) phenotype in cancer cells. While dose escalation of DOX can circumvent such resistance to a degree, this is precluded by the appearance of cardiotoxicity, a particularly debilitating condition in children. In vitro studies have established the ability of the natural phytochemical curcumin to overcome MDR; however, its widespread clinical application is restricted by poor solubility and low bioavailability. Building upon our recently developed polymer nanoparticle of curcumin (NanoCurc or NC) that significantly enhances the systemic bioavailability of curcumin, we synthesized a doxorubicin-curcumin composite nanoparticle formulation called NanoDoxCurc (NDC) for overcoming DOX resistance. Compared to DOX alone, NDC inhibited the MDR phenotype and caused striking growth inhibition both in vitro and in vivo in several models of DOXresistant cancers (multiple myeloma, acute leukemia, prostate and ovarian cancers, respectively). Notably, NDC-treated mice also demonstrated complete absence of cardiac toxicity, as assessed by echocardiography, or any bone marrow suppression, even at cumulative dosages where free DOX and pegylated liposomal DOX (Doxil®) resulted in demonstrable attenuation of cardiac function and hematological toxicities. This improvement in safety profile was achieved through a reduction of DOX-induced intracellular oxidative stress, as indicated by total glutathione levels and glutathione peroxidase activity in cardiac tissue. A composite DOX-curcumin nanoparticle that overcomes both MDR-based DOX chemoresistance and DOX-induced cardiotoxicity holds promise for providing lasting and safe anticancer therapy.

Original languageEnglish (US)
Pages (from-to)640-650
Number of pages11
JournalOncotarget
Volume3
Issue number6
StatePublished - Jun 2012

Fingerprint

Multiple Drug Resistance
Cardiomyopathies
Nanoparticles
Doxorubicin
Polymers
Curcumin
Biological Availability
Phenotype
Phytochemicals
Glutathione Peroxidase
Treatment Failure
Multiple Myeloma
Antineoplastic Agents
Ovarian Neoplasms
Solubility
Glutathione
Echocardiography
Neoplasms
Prostatic Neoplasms
Leukemia

Keywords

  • Curcumin
  • Doxorubicin
  • Multidrug resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Pramanik, D., Campbell, N. R., Das, S., Gupta, S., Chenna, V., Bisht, S., ... Maitra, A. (2012). A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget, 3(6), 640-650.

A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. / Pramanik, Dipankar; Campbell, Nathaniel R.; Das, Samarjit; Gupta, Sonal; Chenna, Venugopal; Bisht, Savita; Sysa-Shah, Polina; Bedja, Djahida; Karikari, Collins; Steenbergen, Charles Jr; Gabrielson, Kathleen L; Maitra, Amarnath; Maitra, Anirban.

In: Oncotarget, Vol. 3, No. 6, 06.2012, p. 640-650.

Research output: Contribution to journalArticle

Pramanik, D, Campbell, NR, Das, S, Gupta, S, Chenna, V, Bisht, S, Sysa-Shah, P, Bedja, D, Karikari, C, Steenbergen, CJ, Gabrielson, KL, Maitra, A & Maitra, A 2012, 'A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy', Oncotarget, vol. 3, no. 6, pp. 640-650.
Pramanik, Dipankar ; Campbell, Nathaniel R. ; Das, Samarjit ; Gupta, Sonal ; Chenna, Venugopal ; Bisht, Savita ; Sysa-Shah, Polina ; Bedja, Djahida ; Karikari, Collins ; Steenbergen, Charles Jr ; Gabrielson, Kathleen L ; Maitra, Amarnath ; Maitra, Anirban. / A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. In: Oncotarget. 2012 ; Vol. 3, No. 6. pp. 640-650.
@article{e041d45faa604f98a144e7f7ddeb774b,
title = "A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy",
abstract = "Acquired chemotherapy resistance is a major contributor to treatment failure in oncology. For example, the efficacy of the common anticancer agent doxorubicin (DOX) is limited by the emergence of multidrug resistance (MDR) phenotype in cancer cells. While dose escalation of DOX can circumvent such resistance to a degree, this is precluded by the appearance of cardiotoxicity, a particularly debilitating condition in children. In vitro studies have established the ability of the natural phytochemical curcumin to overcome MDR; however, its widespread clinical application is restricted by poor solubility and low bioavailability. Building upon our recently developed polymer nanoparticle of curcumin (NanoCurc or NC) that significantly enhances the systemic bioavailability of curcumin, we synthesized a doxorubicin-curcumin composite nanoparticle formulation called NanoDoxCurc (NDC) for overcoming DOX resistance. Compared to DOX alone, NDC inhibited the MDR phenotype and caused striking growth inhibition both in vitro and in vivo in several models of DOXresistant cancers (multiple myeloma, acute leukemia, prostate and ovarian cancers, respectively). Notably, NDC-treated mice also demonstrated complete absence of cardiac toxicity, as assessed by echocardiography, or any bone marrow suppression, even at cumulative dosages where free DOX and pegylated liposomal DOX (Doxil{\circledR}) resulted in demonstrable attenuation of cardiac function and hematological toxicities. This improvement in safety profile was achieved through a reduction of DOX-induced intracellular oxidative stress, as indicated by total glutathione levels and glutathione peroxidase activity in cardiac tissue. A composite DOX-curcumin nanoparticle that overcomes both MDR-based DOX chemoresistance and DOX-induced cardiotoxicity holds promise for providing lasting and safe anticancer therapy.",
keywords = "Curcumin, Doxorubicin, Multidrug resistance",
author = "Dipankar Pramanik and Campbell, {Nathaniel R.} and Samarjit Das and Sonal Gupta and Venugopal Chenna and Savita Bisht and Polina Sysa-Shah and Djahida Bedja and Collins Karikari and Steenbergen, {Charles Jr} and Gabrielson, {Kathleen L} and Amarnath Maitra and Anirban Maitra",
year = "2012",
month = "6",
language = "English (US)",
volume = "3",
pages = "640--650",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "6",

}

TY - JOUR

T1 - A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy

AU - Pramanik, Dipankar

AU - Campbell, Nathaniel R.

AU - Das, Samarjit

AU - Gupta, Sonal

AU - Chenna, Venugopal

AU - Bisht, Savita

AU - Sysa-Shah, Polina

AU - Bedja, Djahida

AU - Karikari, Collins

AU - Steenbergen, Charles Jr

AU - Gabrielson, Kathleen L

AU - Maitra, Amarnath

AU - Maitra, Anirban

PY - 2012/6

Y1 - 2012/6

N2 - Acquired chemotherapy resistance is a major contributor to treatment failure in oncology. For example, the efficacy of the common anticancer agent doxorubicin (DOX) is limited by the emergence of multidrug resistance (MDR) phenotype in cancer cells. While dose escalation of DOX can circumvent such resistance to a degree, this is precluded by the appearance of cardiotoxicity, a particularly debilitating condition in children. In vitro studies have established the ability of the natural phytochemical curcumin to overcome MDR; however, its widespread clinical application is restricted by poor solubility and low bioavailability. Building upon our recently developed polymer nanoparticle of curcumin (NanoCurc or NC) that significantly enhances the systemic bioavailability of curcumin, we synthesized a doxorubicin-curcumin composite nanoparticle formulation called NanoDoxCurc (NDC) for overcoming DOX resistance. Compared to DOX alone, NDC inhibited the MDR phenotype and caused striking growth inhibition both in vitro and in vivo in several models of DOXresistant cancers (multiple myeloma, acute leukemia, prostate and ovarian cancers, respectively). Notably, NDC-treated mice also demonstrated complete absence of cardiac toxicity, as assessed by echocardiography, or any bone marrow suppression, even at cumulative dosages where free DOX and pegylated liposomal DOX (Doxil®) resulted in demonstrable attenuation of cardiac function and hematological toxicities. This improvement in safety profile was achieved through a reduction of DOX-induced intracellular oxidative stress, as indicated by total glutathione levels and glutathione peroxidase activity in cardiac tissue. A composite DOX-curcumin nanoparticle that overcomes both MDR-based DOX chemoresistance and DOX-induced cardiotoxicity holds promise for providing lasting and safe anticancer therapy.

AB - Acquired chemotherapy resistance is a major contributor to treatment failure in oncology. For example, the efficacy of the common anticancer agent doxorubicin (DOX) is limited by the emergence of multidrug resistance (MDR) phenotype in cancer cells. While dose escalation of DOX can circumvent such resistance to a degree, this is precluded by the appearance of cardiotoxicity, a particularly debilitating condition in children. In vitro studies have established the ability of the natural phytochemical curcumin to overcome MDR; however, its widespread clinical application is restricted by poor solubility and low bioavailability. Building upon our recently developed polymer nanoparticle of curcumin (NanoCurc or NC) that significantly enhances the systemic bioavailability of curcumin, we synthesized a doxorubicin-curcumin composite nanoparticle formulation called NanoDoxCurc (NDC) for overcoming DOX resistance. Compared to DOX alone, NDC inhibited the MDR phenotype and caused striking growth inhibition both in vitro and in vivo in several models of DOXresistant cancers (multiple myeloma, acute leukemia, prostate and ovarian cancers, respectively). Notably, NDC-treated mice also demonstrated complete absence of cardiac toxicity, as assessed by echocardiography, or any bone marrow suppression, even at cumulative dosages where free DOX and pegylated liposomal DOX (Doxil®) resulted in demonstrable attenuation of cardiac function and hematological toxicities. This improvement in safety profile was achieved through a reduction of DOX-induced intracellular oxidative stress, as indicated by total glutathione levels and glutathione peroxidase activity in cardiac tissue. A composite DOX-curcumin nanoparticle that overcomes both MDR-based DOX chemoresistance and DOX-induced cardiotoxicity holds promise for providing lasting and safe anticancer therapy.

KW - Curcumin

KW - Doxorubicin

KW - Multidrug resistance

UR - http://www.scopus.com/inward/record.url?scp=84868617917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868617917&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 640

EP - 650

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 6

ER -